Welcome to our dedicated page for Briacell Therapeutics SEC filings (Ticker: BCTXL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Briacell Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Briacell Therapeutics's regulatory disclosures and financial reporting.
BriaCell Therapeutics Corp. reported a larger net loss as it accelerated cancer immunotherapy development. For the nine months ended April 30, 2026, the company lost $22.8 million, up from $18.4 million a year earlier, driven mainly by higher research, development, and clinical trial expenses of $18.7 million versus $14.2 million.
Cash, cash equivalents, and short-term investments totaled $22.8 million, with cash of $6.9 million and positive working capital of $21.8 million. However, a cumulative deficit of $134.3 million and operating cash outflows of $22.7 million over nine months led management to state that substantial doubt exists about BriaCell’s ability to continue as a going concern without additional financing.
Clinically, BriaCell advanced its Bria-IMT™ pivotal Phase 3 study in metastatic breast cancer under FDA Fast Track Designation, reporting extended survival and favorable safety signals, and broadened its pipeline with Bria-OTS™, Bria-OTS+™, and Bria-PROS+™ including new FDA clearance to begin a Phase 1/2a study for Bria-BRES+™.
BriaCell Therapeutics Corp. reported a larger net loss as it accelerated cancer immunotherapy development. For the nine months ended April 30, 2026, the company lost $22.8 million, up from $18.4 million a year earlier, driven mainly by higher research, development, and clinical trial expenses of $18.7 million versus $14.2 million.
Cash, cash equivalents, and short-term investments totaled $22.8 million, with cash of $6.9 million and positive working capital of $21.8 million. However, a cumulative deficit of $134.3 million and operating cash outflows of $22.7 million over nine months led management to state that substantial doubt exists about BriaCell’s ability to continue as a going concern without additional financing.
Clinically, BriaCell advanced its Bria-IMT™ pivotal Phase 3 study in metastatic breast cancer under FDA Fast Track Designation, reporting extended survival and favorable safety signals, and broadened its pipeline with Bria-OTS™, Bria-OTS+™, and Bria-PROS+™ including new FDA clearance to begin a Phase 1/2a study for Bria-BRES+™.
BriaCell Therapeutics Corp. entered a Placement Agency Agreement with ThinkEquity for a best efforts equity offering of 1,449,300 common shares at $3.25 per share. The offering generated gross proceeds of about $4.71 million before fees and expenses.
The company plans to use the net proceeds for working capital, general corporate purposes, and advancing its business objectives. The shares were issued under an effective shelf registration statement on Form S-3. As compensation, BriaCell paid a cash fee of 7.5% of gross proceeds and issued Placement Agent Warrants to buy 72,465 common shares at an exercise price of $4.0625 per share, exercisable immediately and expiring five years after the agreement date.
BriaCell Therapeutics Corp. entered a Placement Agency Agreement with ThinkEquity for a best efforts equity offering of 1,449,300 common shares at $3.25 per share. The offering generated gross proceeds of about $4.71 million before fees and expenses.
The company plans to use the net proceeds for working capital, general corporate purposes, and advancing its business objectives. The shares were issued under an effective shelf registration statement on Form S-3. As compensation, BriaCell paid a cash fee of 7.5% of gross proceeds and issued Placement Agent Warrants to buy 72,465 common shares at an exercise price of $4.0625 per share, exercisable immediately and expiring five years after the agreement date.
BriaCell Therapeutics Corp. is offering 1,449,300 common shares at an offering price of $3.25 per share pursuant to this prospectus supplement.
The placement agent for the offering is ThinkEquity LLC. Gross proceeds at the stated price are $4,710,225, with placement agent commissions of $353,267 (7.5%) and estimated net proceeds to the company of approximately $3.94 million. Closing of the offering is expected on or about June 2, 2026. The prospectus states common shares outstanding following the offering will be 8,699,787, and lists related equity instruments (warrants, options, RSUs, PSUs) with explicit counts and exercise/ conversion prices.
BriaCell Therapeutics Corp. is offering 1,449,300 common shares at an offering price of $3.25 per share pursuant to this prospectus supplement.
The placement agent for the offering is ThinkEquity LLC. Gross proceeds at the stated price are $4,710,225, with placement agent commissions of $353,267 (7.5%) and estimated net proceeds to the company of approximately $3.94 million. Closing of the offering is expected on or about June 2, 2026. The prospectus states common shares outstanding following the offering will be 8,699,787, and lists related equity instruments (warrants, options, RSUs, PSUs) with explicit counts and exercise/ conversion prices.
BriaCell Therapeutics Corp. is furnishing unaudited interim results for its subsidiary BriaPro Therapeutics and outlining a new oncology licensing deal. For the six months ended January 31, 2026, BriaPro recorded a net loss of $472,231, driven mainly by research and development spending of $433,307. The company has negative working capital of $1,638,799 and a cumulative deficit of $1,652,656, and the statements highlight material uncertainty about its ability to continue as a going concern, with operations funded by BriaCell.
On February 18, 2026, BriaPro agreed to acquire an exclusive worldwide license to develop and commercialize Soluble CD80 (sCD80) for cancer from BriaCell, along with related assets. As consideration and in connection with a $3,000,000 BriaCell credit facility, BriaPro will issue 23,972,589 common shares valued at approximately C$1.18 million, increasing BriaCell’s stake to about 78%. BriaPro will owe a 2% royalty on sCD80 sales to the University of Maryland, Baltimore County. Disinterested shareholders approved the transaction on March 5, 2026, and it closed on March 30, 2026.
BriaCell Therapeutics Corp. is furnishing unaudited interim results for its subsidiary BriaPro Therapeutics and outlining a new oncology licensing deal. For the six months ended January 31, 2026, BriaPro recorded a net loss of $472,231, driven mainly by research and development spending of $433,307. The company has negative working capital of $1,638,799 and a cumulative deficit of $1,652,656, and the statements highlight material uncertainty about its ability to continue as a going concern, with operations funded by BriaCell.
On February 18, 2026, BriaPro agreed to acquire an exclusive worldwide license to develop and commercialize Soluble CD80 (sCD80) for cancer from BriaCell, along with related assets. As consideration and in connection with a $3,000,000 BriaCell credit facility, BriaPro will issue 23,972,589 common shares valued at approximately C$1.18 million, increasing BriaCell’s stake to about 78%. BriaPro will owe a 2% royalty on sCD80 sales to the University of Maryland, Baltimore County. Disinterested shareholders approved the transaction on March 5, 2026, and it closed on March 30, 2026.
BriaCell Therapeutics Corp. filed a Form 25 notifying removal of its Warrant class from listing and registration on the Nasdaq Stock Market LLC.
Nasdaq certified compliance with 17 CFR 240.12d2-2 procedures to strike the class and the filing states the issuer complied with the Exchange's voluntary withdrawal requirements. The notice is signed by Tara Petta, Director.
BriaCell Therapeutics Corp. filed a Form 25 notifying removal of its Warrant class from listing and registration on the Nasdaq Stock Market LLC.
Nasdaq certified compliance with 17 CFR 240.12d2-2 procedures to strike the class and the filing states the issuer complied with the Exchange's voluntary withdrawal requirements. The notice is signed by Tara Petta, Director.
BriaCell Therapeutics Corp. has called its 2026 annual general and special meeting for March 5, 2026 in Toronto. Shareholders of record on January 26, 2026, representing 7,250,487 common shares, can vote in person or by proxy.
Investors will vote on appointing MNP LLP as auditor, electing six directors, and re-approving BriaCell’s rolling omnibus equity incentive plan, which allows equity awards up to 15% of shares outstanding, with additional caps for insiders and non-employee directors. The Board unanimously recommends voting “FOR” all three proposals.
BriaCell Therapeutics Corp. has called its 2026 annual general and special meeting for March 5, 2026 in Toronto. Shareholders of record on January 26, 2026, representing 7,250,487 common shares, can vote in person or by proxy.
Investors will vote on appointing MNP LLP as auditor, electing six directors, and re-approving BriaCell’s rolling omnibus equity incentive plan, which allows equity awards up to 15% of shares outstanding, with additional caps for insiders and non-employee directors. The Board unanimously recommends voting “FOR” all three proposals.